Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Financing Activities (2016 - 2025)

Adma Biologics (ADMA) has disclosed Cash from Financing Activities for 13 consecutive years, with -$9.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 70.61% year-over-year to -$9.1 million, compared with a TTM value of -$44.0 million through Dec 2025, up 24.49%, and an annual FY2025 reading of -$44.0 million, up 24.49% over the prior year.
  • Cash from Financing Activities was -$9.1 million for Q4 2025 at Adma Biologics, up from -$27.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $62.7 million in Q4 2022 and bottomed at -$39.0 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $4.4 million, with a median of -$340520.5 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities surged 1014330.22% in 2021, then crashed 6221.88% in 2024.
  • Year by year, Cash from Financing Activities stood at $53.8 million in 2021, then rose by 16.58% to $62.7 million in 2022, then tumbled by 162.15% to -$39.0 million in 2023, then increased by 20.44% to -$31.0 million in 2024, then surged by 70.61% to -$9.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ADMA at -$9.1 million in Q4 2025, -$27.8 million in Q3 2025, and $48000.0 in Q2 2025.